Showing 1 - 6 results of 6 for search 'David Dornan', query time: 0.03s Refine Results
  1. 1
    miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

    miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. by Michael S Hwang, Nancy Yu, Susanna Y Stinson, Peng Yue, Robert J Newman, Bernard B Allan, David Dornan

    Published 2013-01-01
    Get full text
    Article
  2. 2
    Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

    Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemother... by Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Braziel, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, Lisa M. Rimsza

    Published 2012-06-01
    Get full text
    Article
  3. 3
    Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45

    Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45 by Daniel O. Persky, David Dornan, Bryan H. Goldman, Rita M. Braziel, Richard I. Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, Thomas P. Miller, Lisa M. Rimsza

    Published 2012-11-01
    Get full text
    Article
  4. 4
    603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration

    603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe... by David Jackson, Shelley Ackerman, David Dornan, Michael Alonso, Felix Hartmann, Cecelia Pearson, Joseph Gonzalez, Po Yi Ho, Samuel Kimmey, Andrew Luo, Benjamin Ackerman, Arthur Lee, Richard Laura, Jason Paik, Karla Henning, Steven Chapin, Bruce Devens, Sean Bendall, Edgar Engleman

    Published 2020-11-01
    Article
  5. 5
    401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

    401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2... by Marcin Kowanetz, Manish Sharma, Jeeyun Lee, Leisha Emens, Keun-Wook Lee, Yoon-Koo Kang, Paula Pohlmann, Glenn Hanna, Ecaterina Ileana Dumbrava, Daniel Catenacci, Dejan Juric, Bob Li, Kathleen Moore, Mark Pegram, Antoinette Tan, Shelley Ackerman, Heidi LeBlanc, David Dornan, Michael Alonso, Edith Perez

    Published 2020-11-01
    Article
  6. 6
    784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors

    784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors by Marcin Kowanetz, Shelley Ackerman, David Dornan, Michael Alonso, Edith Perez, Cecelia Pearson, Arthur Lee, Karla Henning, Steven Chapin, LIsa Blum, Angela Luo, Matthew Zhou, Brian Safina, Amreen Husain, William Mallet, Rishali Gadkari, Laughing Bear Torrez Dulgeroff, AAngela Luondrew Luo, Jennifer Melrose, Jess Nolin, Puneet Anand, Ganapathy Sarma, Liz Bogaert, Romas Kudirka, Yuyi Shen

    Published 2021-11-01
    Article

Search Tools: